AI-generated analysis. Always verify with the original filing.
Xilio Therapeutics announced fourth quarter and full year 2025 financial results on March 23, 2026, reporting collaboration and license revenue of $13.7 million for Q4 and net income of $10.4 million, alongside a cash position of $137.5 million as of December 31, 2025. The company provided pipeline updates on XTX501 and masked T cell engagers, with cash runway extended through the end of 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 23, 2026, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and y
Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished
| Metric | Value | Basis |
|---|---|---|
| Collaboration and License Revenue | $13.70 | |
| Collaboration and License Revenue | $43.80 | |
| Research & Development Expenses | $18.10 | |
| Research & Development Expenses | $56.00 | |
| General & Administrative Expenses | $7.40 | |
| General & Administrative Expenses | $29.70 | |
| Net Income (Loss) | $10.40 | |
| Net Income (Loss) | $-35.00 |